Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • New drug increases...

    New drug increases survival in young women with advanced breast cancer

    Written by Medha Baranwal Baranwal Published On 2019-06-04T19:30:39+05:30  |  Updated On 4 Jun 2019 7:30 PM IST
    New drug increases survival in young women with advanced breast cancer

    New drug shows increased survival rate in young women with breast cancer. The drug works by inhibiting the activity of cancer-cell promoting enzymes.


    The treatment is less toxic than traditional chemotherapy because it more selectively targets cancerous cells, blocking their ability to multiply.


    The study, touted as one of the greatest advances in the field of breast cancer treatment in recent decades, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three and a half years. The mortality rate was 29 percent less when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.


    The results of the international clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.


    The study conducted by Sara Hurvitz and colleagues focused on a form of breast cancer which is fueled by the hormone estrogen and which accounts for two-thirds of all cases among younger women. It is generally treated by therapies that block the hormone's production.


    "You actually can get synergy, or better response, better cancer kill, by adding one of these cell-cycle inhibitors" on top of the hormone-blocking therapy, said Hurvitz.


    Also Read: High intake of vitamin D, calcium and phosphorus may reduce breast cancer risk

    Breast cancer is the most common cancer among Indian women -- approximately 25% of the female cancer cases in India are BC - with an age-adjusted rate of 25.8 cases per 100,000 women and a mortality rate of 12.7 per 100,000 women.


    The new trial involved the analysis of 670 women with stage 4 advanced cancer for which they had not received prior hormone-blocking therapy."These are patients who tend to be diagnosed later, at a later stage in their disease, because we don't have great screening modalities for young women," said Hurvitz.


    In addition, patients who develop breast cancer early tend to have more complex cases.


    "That's what makes us so excited because it's a therapy that's affecting so many patients with advanced disease," added Hurvitz.


    A pill is administered daily for 21 days followed by seven days off to allow the body time to recover since two-thirds of patients have a moderate to a severe drop in white cell count.


    Also Read: Annual mammography for breast cancer screening best, recommends literature review

    Jamie Bennett, a spokeswoman for Novartis, which markets the drug under the brand name Kisqali and funded the research, said it cost $12,553 for a 28-day dose. There is no cure for metastatic breast cancer and the majority of the women on the drug will require some form of therapy for the rest of their lives.


    Moving forward, Hurvitz said she was interested in investigating whether ribociclib could help nip cancer in the bud at an earlier stage.


    "We want to go and look at those women diagnosed with early-stage disease, small tumors, tumors that haven't gone to the lymph nodes or haven't gone to other parts of the body and see if we can stop it from returning later from metastasizing," she said.


    The enrollment phase of a new global clinical trial is now underway.

    breast cancerbreast cancer drugbreast cancer treatmentcancer survivalcell-cycle inhibitor ribociclibmetastatic breast cancermortalitynew breast cancer drugribociclibSara Hurvitzsurvivalsurvival rateyoung women

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok